Gilead adds seladelpar, a PBC candidate now under priority review, to liver disease arsenal 

Long-term, biomarkers will replace biopsies in NASH. Short-term, they’re aiding patient recruitment.

What’s needed to set the first efficacy benchmarks for NASH